Biotechnology

Filter

Current filters:

None

Popular Filters

1 to 25 of 2289 results

NICE U-turn on Celgene’s Revlimid for myelodysplastic syndromes

NICE U-turn on Celgene’s Revlimid for myelodysplastic syndromes

20-08-2014

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) has issued final draft…

BiotechnologyCelgene Corp.Myelodysplastic syndromesOncologyPricingRegulationRevlimidUK

Genzyme’s Cerdelga gets FDA approval for Gaucher disease

Genzyme’s Cerdelga gets FDA approval for Gaucher disease

20-08-2014

The US Food and Drug Administration late yesterday approved Cerdelga (eliglustat) for the long-term treatment…

ActelionBiotechnologyCerdelgaCerezymeGenzymeRare diseasesRegulationSanofiUSAZavesca

Novartis makes investment in stem cell company Gamida Cell with option agreement

Novartis makes investment in stem cell company Gamida Cell with option agreement

19-08-2014

Swiss drug major Novartis has signed an investment and option agreement with Israeli stem cell specialist…

BiotechnologyFinancialGamida CellHematologyIsraelNovartisStem cell specialistSwitzerland

HUYA to partner with Changzhou Center for Biotech Development to promote local innovation

HUYA to partner with Changzhou Center for Biotech Development to promote local innovation

18-08-2014

Chinese company HUYA Bioscience has announced a partnership with Changzhou Center for Biotech Development,…

BiotechnologyChangzhouChinaHUYA BioscienceResearch

Biogen Idec’s Plegridy gains US approval for multiple sclerosis

Biogen Idec’s Plegridy gains US approval for multiple sclerosis

17-08-2014

The US Food and Drug Administration has approved US biotech firm Biogen Idec’s (Nasdaq: BIIB) Plegridy…

Biogen IdecBiotechnologyNeurologicalPlegridyRegulationUSA

Gilead gets favorable ruling in Roche arbitration

Gilead gets favorable ruling in Roche arbitration

17-08-2014

US biotech major Gilead Sciences said on Friday in a Security and Exchange Commission filing that an…

Anti-viralsArbitrationBiotechnologyBusiness FinanceBusiness FinanceGilead SciencesLegalPatentsPharmassetRocheSovaldiUSA

Amgen issues voluntary recall of Aranesp prefilled syringes in certain countries

Amgen issues voluntary recall of Aranesp prefilled syringes in certain countries

15-08-2014

USA-based Amgen initiated a voluntary recall on June 26 for nine packaged lots of anemia drug Aranesp…

AmgenAnemiaAranespBiotechnologyMarkets & MarketingOncologyRegulation

Ligand signs Captisol license deal with Avion Pharmaceuticals

Ligand signs Captisol license deal with Avion Pharmaceuticals

15-08-2014

Ligand Pharmaceuticals has signed a commercial license agreement with fellow USA-based Avion Pharmaceuticals,…

Avion PharmaceuticalsBiotechnologyBusiness FinanceCaptisolLicensingLigand PharmaceuticalsUSA

Oxford BioMedica appoints former Aeterna Zentaris senior vice president Paul Blake as chief development officer

Oxford BioMedica appoints former Aeterna Zentaris senior vice president Paul Blake as chief development officer

15-08-2014

British gene and cell therapy company Oxford BioMedica has appointed Paul Blake as chief development…

BiotechnologyBoardroomOxford BioMedicaPaul BlakeUK

Positive draft guidance for hep C drug Sovaldi from UK’s NICE

Positive draft guidance for hep C drug Sovaldi from UK’s NICE

15-08-2014

In further draft guidance published today, UK drugs watchdog the National Institute for Health and Care…

Anti-viralsBiotechnologyGilead SciencesHepatitis CPricingRegulationRibavirinSovaldiUK

iBio collaborates with Kanematsu Chemicals to target Japanese market

iBio collaborates with Kanematsu Chemicals to target Japanese market

14-08-2014

USA-based iBio Inc and Japan’s Kanematsu Chemicals, part of Kanematsu Corp have entered into a collaboration…

BiotechnologyBusiness FinanceiBio IncJapanKanematsuLicensingPharmacologyVaccines

Amgen’s Kyprolis failed to meet primary endpoint in multiple myeloma trial

Amgen’s Kyprolis failed to meet primary endpoint in multiple myeloma trial

14-08-2014

USA-based Amgen, the world’s leading independent biotech firm, and its subsidiary Onyx Pharmaceuticals,…

Advanced refractory multiple myelomaAmgenBiotechnologyKyprolisOncologyOnyx PharmaceuticalsResearchUSA

Rigel’s R348 fails to meet endpoints in Ph II dry eye study

13-08-2014

Clinical-stage US drug developer Rigel Pharmaceuticals says that R348, its ophthalmic JAK/SYK inhibitor,…

BiotechnologyDry eye diseasefostamatinibOphthalmicsR118R348ResearchRigel Pharmaceuticals

1 to 25 of 2289 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top